Contrasting Catalent (CTLT) and Its Rivals

Catalent (NYSE: CTLT) is one of 103 publicly-traded companies in the “Pharmaceuticals” industry, but how does it compare to its rivals? We will compare Catalent to related businesses based on the strength of its valuation, institutional ownership, profitability, risk, dividends, analyst recommendations and earnings.

Institutional and Insider Ownership

99.5% of Catalent shares are owned by institutional investors. Comparatively, 44.8% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 1.7% of Catalent shares are owned by company insiders. Comparatively, 11.4% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Catalent and its rivals revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Catalent $2.08 billion $109.80 million 45.09
Catalent Competitors $8.17 billion $1.09 billion 152.01

Catalent’s rivals have higher revenue and earnings than Catalent. Catalent is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Catalent and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Catalent 5.01% 23.97% 5.24%
Catalent Competitors -2,402.60% -68.80% -7.35%

Analyst Ratings

This is a summary of recent ratings and target prices for Catalent and its rivals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Catalent 0 2 5 0 2.71
Catalent Competitors 873 3797 6767 181 2.54

Catalent presently has a consensus target price of $43.71, suggesting a potential upside of 11.43%. As a group, “Pharmaceuticals” companies have a potential upside of 26.50%. Given Catalent’s rivals higher possible upside, analysts clearly believe Catalent has less favorable growth aspects than its rivals.

Volatility & Risk

Catalent has a beta of 1.41, indicating that its share price is 41% more volatile than the S&P 500. Comparatively, Catalent’s rivals have a beta of 35.07, indicating that their average share price is 3,407% more volatile than the S&P 500.

Summary

Catalent rivals beat Catalent on 7 of the 13 factors compared.

Catalent Company Profile

Catalent, Inc. provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels. The Drug Delivery Solutions segment is engaged in the formulation, development and manufacturing of prescription and consumer and animal health products; blow-fill seal unit dose manufacturing; biologic cell line development; analytical and bioanalytical development, and testing services. The Clinical Supply Services segment is engaged in manufacturing, packaging, labeling, storage, distribution and inventory management for clinical trials of drugs and biologics for patient kits; FastChain clinical supply service; clinical e-solutions and informatics, and global comparator sourcing services.

Receive News & Ratings for Catalent Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply